Search research articles
Contact Us
Filters
Showing results (1-10 of 11) with videos related to
Page
of 2
Sort By:
Journal of Chemical Information and Modeling
|
March 9, 2011
Intuitive patent Markush structure visualization tool for medicinal chemists
Wei Deng, Steven J Berthel, W Venus So
ACS Pharmacology & Translational Science
|
July 20, 2023
DAIKON: A Data Acquisition, Integration, and Knowledge Capture Web Application for Target-Based Drug Discovery
Siddhant Rath, Saswati Panda, James C Sacchettini, et al.
Expert Opinion on Therapeutic Patents
|
December 16, 2010
Novel glucokinase activators: a patent review (2008 - 2010)
Ramakanth Sarabu, Steven J Berthel, Robert F Kester, et al.
Journal of Cheminformatics
|
May 15, 2026
Deep learning for assay nuisance compound detection using a gated co-attention graph embedding model (CAGE-Fusion)
Siddhant Rath, Saswati Panda, Steven J Berthel, et al.
Drug Discovery Today
|
May 2, 2026
Building and managing a complex drug discovery consortium: Insights from the tuberculosis drug accelerator
Kelsey L Briggs, Betsy J Russell, Peter Warner, et al.
Anti-Cancer Drugs
|
May 2, 2002
Identification of phenyl-pyridine-2-carboxylic acid derivatives as novel cell cycle inhibitors with increased selectivity for cancer cells
Steven J Berthel, Ian M Marks, Xuefeng Yin, et al.
Handbook of Experimental Pharmacology
|
April 13, 2011
Research and development of glucokinase activators for diabetes therapy: theoretical and practical aspects
Franz M Matschinsky, Bogumil Zelent, Nicolai M Doliba, et al.
ACS Medicinal Chemistry Letters
|
June 6, 2014
Identification of RO4597014, a Glucokinase Activator Studied in the Clinic for the Treatment of Type 2 Diabetes
Yimin Qian, Wendy L Corbett, Steven J Berthel, et al.
EMBO Molecular Medicine
|
April 7, 2026
Integrating chemical, genetic, and feasibility assessments for anti-tubercular target validation
Dirk Schnappinger, Steven J Berthel, Helena I M Boshoff, et al.
Nature Medicine
|
July 6, 2021
The Tuberculosis Drug Accelerator at year 10: what have we learned?
Bree B Aldridge, David Barros-Aguirre, Clifton E Barry, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 11) with videos related to
Sort By:
Page
of 2
Journal of Chemical Information and Modeling
|
March 9, 2011
Intuitive patent Markush structure visualization tool for medicinal chemists
Wei Deng, Steven J Berthel, W Venus So
ACS Pharmacology & Translational Science
|
July 20, 2023
DAIKON: A Data Acquisition, Integration, and Knowledge Capture Web Application for Target-Based Drug Discovery
Siddhant Rath, Saswati Panda, James C Sacchettini, et al.
Expert Opinion on Therapeutic Patents
|
December 16, 2010
Novel glucokinase activators: a patent review (2008 - 2010)
Ramakanth Sarabu, Steven J Berthel, Robert F Kester, et al.
Journal of Cheminformatics
|
May 15, 2026
Deep learning for assay nuisance compound detection using a gated co-attention graph embedding model (CAGE-Fusion)
Siddhant Rath, Saswati Panda, Steven J Berthel, et al.
Drug Discovery Today
|
May 2, 2026
Building and managing a complex drug discovery consortium: Insights from the tuberculosis drug accelerator
Kelsey L Briggs, Betsy J Russell, Peter Warner, et al.
Anti-Cancer Drugs
|
May 2, 2002
Identification of phenyl-pyridine-2-carboxylic acid derivatives as novel cell cycle inhibitors with increased selectivity for cancer cells
Steven J Berthel, Ian M Marks, Xuefeng Yin, et al.
Handbook of Experimental Pharmacology
|
April 13, 2011
Research and development of glucokinase activators for diabetes therapy: theoretical and practical aspects
Franz M Matschinsky, Bogumil Zelent, Nicolai M Doliba, et al.
ACS Medicinal Chemistry Letters
|
June 6, 2014
Identification of RO4597014, a Glucokinase Activator Studied in the Clinic for the Treatment of Type 2 Diabetes
Yimin Qian, Wendy L Corbett, Steven J Berthel, et al.
EMBO Molecular Medicine
|
April 7, 2026
Integrating chemical, genetic, and feasibility assessments for anti-tubercular target validation
Dirk Schnappinger, Steven J Berthel, Helena I M Boshoff, et al.
Nature Medicine
|
July 6, 2021
The Tuberculosis Drug Accelerator at year 10: what have we learned?
Bree B Aldridge, David Barros-Aguirre, Clifton E Barry, et al.
Page
of 2